Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab plus corticosteroids for first-line treatment of severe acute graft-versus-host disease
NL-OMON60485Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of siltuximab and corticosteroids in Acute Graft-Versus-Host Disease (aGvHD), sponsored by University Medical Center Groningen. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
siltuximabcorticosteroids
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON60485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60485.